Global Peptic Ulcer Drugs Market - Forecast To 2022

Global Peptic Ulcer Drugs Market - Forecast To 2022

ID: MRFR/Pharma/1812-HCRR | September, 2018 | Region: Global | 85 pages | Half-Cooked Research Reports

Global Peptic Ulcer Drugs Market Information, by Pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by Clinical Application (gastric ulcers, duodenal ulcer, esophageal ulcer) - Forecast Till 2022

Market Synopsis of Global Peptic Ulcer Drugs Market:

Market Scenario:

Peptic ulcer drugs are used to treat erosion of the gastrointestinal lining due to a variety of factors. Peptic ulcer is the result of an imbalance between aggressive and defensive fluids in the stomach. Peptic ulcer includes gastric, esophageal and duodenal ulcer. The global peptic ulcer drugs market was valued at approximately $29 billion in 2015, and is expected to reach $36.27 billion by 2022. Thus, the market is expected to show an average growth at a CAGR of 3.8 % from 2016 to 2022.

The major driving factors for petic ulcers drug market are stress, drug induced ulcers, growing rate of infection by H.Pyrroli, changes in food, rise in cancer, tobacco and alcohol use. Constraining factors of this market are patent expiry, comparatively good treatment regimen of proton pump inhibitors, resistance of H.Pyrolli, extreme market fragmentation into many companies and great penetration of generics.


Study Objectives Global Peptic Ulcer Drugs Market:


  • To provide detail analysis of the market structure along with forecast for the next 5years of various segments and sub-segments of the global peptic ulcer drugs market.

  • To provide an insight about factors affecting the market growth.

  • To analyze the market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.

  • To provide past and estimated future revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospective.

  • To provide country level analysis of the market for segments such as by pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others) and by clinical application (gastric ulcers, duodenal ulcer, esophageal ulcer)

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape of the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research & developments globally.




Global Peptic Ulcer Drugs Market, by Region 2015 & 2022 (USD million):

Global Peptic Ulcer Drugs Market

Intended Audience:



  • Global peptic ulcer drugs manufacturers

  • Global peptic ulcer drugs suppliers

  • Research and development Laboratories

  • Market research and consulting service providers


Key Players For Global Peptic Ulcer Drugs Market:
Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. Helicure AB and Eumedica Pharmaceuticals

Segments:
Global peptic ulcer drugs market has been segmented on the basis of pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by clinical application (gastric ulcers, duodenal ulcer, esophageal ulcer) and region.

Regional Analysis of Global Peptic Ulcer Drugs Market:
Globally North America is the largest market of global peptic ulcer drugs. Europe is the second largest market for global peptic ulcer drugs. Soon the market of peptic ulcer drugs will be dominated by developing regions particularly Asia Pacific which will be the fastest growing region.

The report of  Global Peptic Ulcer Drugs Market by Market Research Future comprises extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insights of the market and industry performance. The report gives a clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies used by  top key players in the industry. The report also gives a broad study of the different market segments and regions.

Table of Contents

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s Five Forces model

4.1.1 Bargaining Power of suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

5 Global Peptic Ulcer drugs Market, by Pharmacological class

5.1 Introduction

5.1.2 Proton Pump Inhibitors (PPIs)

5.1.3 Anti-Histamines

5.1.4 H2 antagonists

5.1.5 Antacids

5.1.6 Antibiotics

5.1.7 Others

6 Global Peptic Ulcer drugs Market, by Clinical Application

6.1 Introduction

6.1.1 Gastric ulcers

6.1.2 Duodenal Ulcer

6.1.3 Esophageal Ulcer

7 Global Peptic Ulcer Drugs Market, By Regions

7.1 Introduction

7.1.1 Americas

7.1.1.1 North America

7.1.1.2 South America

7.1.2 Europe

7.1.2.1 Germany

7.1.2.2 France

7.1.2.3 UK

7.1.2.4 Italy

7.1.2.5 Spain

7.1.2.6 Rest of Europe

7.1.3 Asia Pacific

7.1.3.1 Japan

7.1.3.2 China

7.1.3.3 India

7.1.3.4 Republic of Korea

7.1.3.5 Rest of Asia Pacific

7.1.4 Middle East & Africa

8 Company Landscape

8.1 Introduction

8.1.1 Mergers Acquisitions

8.1.2 Collaborations

8.1.3 Release/New Product Launches

8.1.4 Other (Expansion, Updates, Partnership)

9 Company Profile

9.1 Novartis AG

9.1.1 Company Overview

9.1.2 Product/Business Segment Overview

9.1.3 Financials

9.1.4 Key Developments

9.1.5 SWOT Analysis

9.2 Daiichi Sankyo Company Limited

9.2.1 Overview

9.2.2 Product/Business Segment Overview

9.2.3 Financials

9.2.4 Key Developments

9.2.5 SWOT Analysis

9.3 Acetelion Ltd

9.3.1 Overview

9.3.2 Product/Business Segment Overview

9.3.3 Financials

9.3.4 Key Developments

9.3.5 SWOT Analysis

9.4 Boehringer Ingelheim

9.4.1 Overview

9.4.2 Product/Business Segment Overview

9.4.3 Financials

9.4.4 Key Developments

9.4.5 SWOT Analysis

9.5 Sanofi S.A.

9.5.1 Overview

9.5.2 Product/Business Segment Overview

9.5.3 Financials

9.5.4 Key Developments

9.5.5 SWOT Analysis

9.6 Astra Zeneca

9.6.1 Overview

9.6.2 Product/Business Segment Overview

9.6.3 Financials

9.6.4 Key Developments

9.6.5 SWOT Analysis

9.7 Ranbaxy Laboratories Limited, Inc.

9.7.1 Overview

9.7.2 Product/Business Segment Overview

9.7.3 Financials

9.7.4 Key Developments

9.7.5 SWOT Analysis

9.8 Takeda Pharmaceuticals Company Limited

9.8.1 Overview

9.8.2 Product/Business Segment Overview

9.8.3 Financials

9.8.4 Key Developments

9.8.5 SWOT Analysis

9.9 Pfizer Inc.

9.9.1 Overview

9.9.2 Product/Business Segment Overview

9.9.3 Financials

9.9.4 Key Developments

9.9.5 SWOT Analysis

9.9 Helicure AB

9.9.1 Overview

9.9.2 Product/Business Segment Overview

9.9.3 Financials

9.9.4 Key Developments

9.9.5 SWOT Analysis

9.9 Eumedica pharmaceuticals

9.9.1 Overview

9.9.2 Product/Business Segment Overview

9.9.3 Financials

9.9.4 Key Developments

9.9.5 SWOT Analysis

10 Others

11 Appendix



List of Tables

TABLE 1 GLOBAL PEPTIC ULCER DRUGS MARKET, 2013-2022 (USD MILLION)

TABLE 2 GLOBAL PEPTIC ULCER DRUGS MARKET, BY PHARMACOLOGICAL CLASS 2013-2022 (USD MILLION)

TABLE 3 GLOBAL PEPTIC ULCER DRUGS MARKET, BY CLINICAL APPLICATION, 2013-2022 (USD MILLION)

TABLE 4 GLOBAL PEPTIC ULCER DRUGS MARKET, BY REGION, 2013-2022 (USD MILLION)



List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL PEPTIC ULCER DRUGS MARKET, BY PHARMACOLOGICAL CLASS

FIGURE 4 GLOBAL PEPTIC ULCER DRUGS MARKET, BY CLINICAL APPLICATION

FIGURE 5 GLOBAL PEPTIC ULCER DRUGS MARKET, BY REGION

FIGURE 6 GLOBAL PEPTIC ULCER DRUGS MARKET: COMPANY SHARE ANALYSIS, 2015 (%)